Search Within

Michael Scordo

Formats
  1. Meeting Abstract (250)
  2. Journal Article (104)
  3. Research Letter (15)
  4. Correspondence (7)
  5. Editorial (5)
  6. Review (4)
  7. Book Section (1)
  8. Guidelines (1)
Groups
  1. Bone Marrow Transplant (387)
  2. CTCR Scholars (387)
  3. Center for Hematologic Malignancies (387)
  4. Department of Medicine (387)
  5. Hematologic Malignancies, Division of (387)
  6. Survivorship Research (338)

More Groups

People
  1. Gunjan Shah (298)
  2. Sergio Giralt (278)
  3. Miguel-Angel Perales (177)
  4. Sean Devlin (152)
  5. Heather Landau (141)
  6. Parastoo Dahi (140)

More People

Years
  1. 2025 (22)
  2. 2024 (72)
  3. 2023 (81)
  4. 2022 (49)
  5. 2021 (27)
  6. 2020 (53)

More Years

Publications
  1. Blood (123)
  2. Biology of Blood and Marrow Transplantation (56)
  3. Clinical Lymphoma, Myeloma and Leukemia (36)
  4. Bone Marrow Transplantation (26)
  5. Blood Advances (21)
  6. Transplantation and Cellular Therapy (15)

More Publications

Publishers
  1. American Society of Hematology (144)
  2. Elsevier Inc. (122)
  3. Nature Publishing Group (40)
  4. American Society of Clinical Oncology (14)
  5. Wiley Blackwell (9)
  6. Oxford University Press (7)

More Publishers

Results (387)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Toxicities and outcomes for patients with CNS lymphoma (CNSL) consolidated with high-dose therapy and autologous stem cell transplantation (HDT-ASCT) using thiotepa, pharmacokinetically-targeted (PR) busulfan (Bu), cyclophosphamide (TBC) conditioning
    Meeting Abstract

    Scordo, M.; Bhatt, V.; Hsu, M.; Omuro, A. M.; Matasar, M. J.; DeAngelis, L.; Dahi, P.; Moskowitz, C. H.; Giralt, S. A.; Sauter, C. S.
    Biology of Blood and Marrow Transplantation (2016)

    Fulltext@MSK | Save
  • A detailed evaluation of transplant-related toxicities and outcome for patients with CNS lymphoma (CNSL) consolidated with high-dose therapy and autologous stem cell transplantation (HDT-ASCT) using thiotepa, busulfan (Bu), cyclophosphamide (TBC) conditioning
    Meeting Abstract

    Scordo, M.; Bhatt, V.; Hsu, M.; Omuro, A. M.; Matasar, M. J.; DeAngelis, L.; Dahi, P. B.; Moskowitz, C. H.; Giralt, S. A.; Sauter, C. S.
    Blood (2015)

    Fulltext@MSK | Save
  • Outcomes of pharmacokinetically (PK) directed busulfan in combination with thiotepa & cyclophosphamide (TBC) conditioning with HDT-ASCT in patients with primary & secondary CNS lymphoma
    Meeting Abstract

    Bhatt, V.; Scordo, M.; Hsu, M.; Omuro, A. M.; DeAngelis, L.; Lin, A.; Matasar, M. J.; Dahi, P. B.; Moskowitz, C. H.; Giralt, S. A.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Osteonecrosis of the jaw a new complication related to Ipilimumab
    Journal Article

    Owosho, A. A.; Scordo, M.; Yom, S. K.; Randazzo, J. ; Chapman, P. B.; Huryn, J. M.; Estilo, C. L.
    Oral Oncology (2015)

    Fulltext@MSK | Save
  • Site and timing of first relapse in stage III melanoma patients: Implications for follow-up guidelines
    Journal Article

    Romano, E.; Scordo, M.; Dusza, S.; Coit, D. G.; Chapman, P. B.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Characteristics of first relapse in stage III melanoma patients with no evidence of disease (NED): Guidelines for follow-up
    Meeting Abstract

    Romano, E.; Scordo, M.; Chapman, P.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Sequential radioimmunotherapy with tositumomab/iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions
    Meeting Abstract

    Zelenetz, A. D.; Noy, A.; Pandit-Taskar, N.; Scordo, M.; Rijo, I.; Zhou, Y.; O'Donoghue, J. A.; Divgi, C.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save